The efficacy of oral versus intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty

A meta-analysis

Fei Wang, MD, Kun-Chi Zhao, MM, Ming-Ming Zhao, MM, Dong-Xu Zhao, MD

1. Introduction

Total knee and hip arthroplasty (TKA and THA) has shown well-recognized efficacy in improving functional outcomes as well as in relieving pain for patients with joint degeneration. With the aging population, the number of TKAs is increasing. However, arthroplasties were associated with substantial bleeding.[1,2]

Thus, a considerable number of patients require blood transfusions in order to treat anemia. As known, allogenic blood transfusion was associated with numerous adverse reactions including anaphylactic reactions, infectious diseases, as well as metabolic disorders prolonging the length of hospital stays, and resulting in serious medical costs.

Numerous methods have been implemented to minimize perioperative blood loss including drug intervention, autologous donation, perioperative hemodilution, minimally invasive surgery, blood salvage, and reinfusion.[3,4] However, high incidence of blood transfusion remains a major concern.

Tranexamic acid (TXA), a 4-aminomethyl cyclohexane-carboxylic acid, is a synthetic amino acid derivative of lysine where the drug binds to the lysine site of the plasminogen in order to promote clot stabilization, thereby inhibiting clot degradation.[5] A majority of orthopedists focused on intravenous and topical administration of TXA. Published articles have indicated that both intravenous and topical application of TXA were associated with improved outcomes in total joint arthroplasties (TJAs).[6,7] Oral TXA was also effective in reductions in blood loss, and transfusion requirements and it was estimated to be more cost effective than the intravenous application.[8]

Despite these apparent advantages, whether oral TXA would be equivalent to intravenously in reducing blood loss in TJA...
remains unclear. Thus, we conducted a systemic review and meta-analysis to compare the efficacy and safety between oral and intravenous TXA in patients undergoing joint arthroplasties.

2. Methods

This systematic review was reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. No ethical approval was required because this paper was based on the previous articles.

2.1. Search methodology

Studies were retrieved from the databases of Pubmed (1966–2018.06), Embase (1980–2018.06), and the Cochrane Central Register of Controlled Trials (1980–2018.06), Web of Science (1966–2018.06), and Google scholar (1966–2018.06). Reference lists of relevant articles were manually searched to identify additional trials. No restrictions were imposed on language. A structured search was performed using the following search string: “Total knee replacement or arthroplasty,” “Total hip replacement or arthroplasty,” “tranexamic acid,” “intravenous,” and “oral.”

2.2. Inclusion criteria

(1) Patients: adult patients with end-stage joint osteoarthritis, rheumatoid arthritis, and osteonecrosis of the femoral head, who prepared for TJA.
(2) Interventions: The experiential group received the intravenous form of TXA.
(3) Comparisons: Oral form of TXA.
(4) Outcomes: Total blood loss, hemoglobin reduction, transfusion requirements, duration of hospitalization, and thrombotic complications including deep vein thrombosis (DVT) and pulmonary embolism (PE).
(5) Study design: Randomized control trials (RCTs) and non-RCT.

2.3. Selection criteria

All relevant studies were collected and duplicate literatures were excluded. Then, 2 researchers independently excluded studies by reading titles and abstracts. At last, the irrelevant studies were removed following inclusion criteria. If no consensus was reached, a third investigator was consulted.

2.4. Date extraction

The available data were extracted independently from the included studies by 2 reviewers. The information included author name, publishing year, age, sample size, gender, intervention procedure, transfusion trigger and follow-up. We send emails to authors to obtain incomplete outcome data.

2.5. Quality assessment

The methodological qualities of included studies were assessed independently by the 2 reviewers described by the Cochrane Collaboration for Systematic Reviews. We conducted a “risk of bias” table including the following key points: random sequence generation, allocation concealment, blinding, incomplete outcome data, free of selective reporting and other bias and each item was recorded by “Yes”- “No”- or “Unclear”. The Methodological Index for Non-Randomized Studies (MINORS) scale was applied to evaluate non-RCTs with scores ranging 0 to 24.

2.6. Statistical methods

Stata 11.0 software was utilized for the meta-analysis. Continuous various outcomes, such as the total blood loss, hemoglobin decline, and length of stay were all expressed as the weighted mean difference (WMD) with a 95% confidence intervals (CIs). The results of dichotomous outcomes (transfusion rate, DVT, PE) were expressed as a risk difference (RD) with 95% confidence intervals (CIs). The statistical heterogeneity was determined by the Chi-squared test in accordance with the value of $P$ and $I^2$. If $I^2 > 50\%$, $P < .05$, statistical was considered to be heterogeneous, we used a random-effects model to analysis the data. Otherwise, the fixed-effects model was performed to conduct meta-analysis.

3. Results

3.1. Search result

Four hundred twenty-five studies were identified from databases. According to the inclusion criteria, 419 studies were excluded. No gray paper was included. Finally, 4 RCTs[10–13] and 2 non-RCT[14,15] which published from 2004 to 2017 were included in our study and includes 621 participates in the TXA groups and 2963 patients in the control groups. The search process was performed as presented in Fig. 1.

3.2. Study characteristics

The basic information of the included articles are concluded in Table 1. The included articles were published from 2004 to 2017. The sample size ranged from 40 to 2940 and mean age of patients ranged from 55 to 69 years. Duration follow-up ranged from 2 to 6 months.

3.3. Risk of bias assessment

Cochrane Collaboration’s tool is applied to evaluate the risk of bias (Tables 2 and 3). Randomization was performed in all RCTs[10–13] which mentioned that the list of random numbers were generated from computers. All articles[11–13] used sealed envelopes for allocation concealment. Double blinding was shown on 3 RCTs. It was not clear whether assessors were blinded. Two non-RCTs were appraised by the MINORS[9] (Table 4).

3.4. Meta-analysis results

3.4.1. Total blood loss

All studies[10–15] provided the total blood loss after TJA. No significant statistical heterogeneity was found ($\chi^2 = 1.03$, df = 5, $I^2 = 0.0\%$, $P = .960$) and a fixed-effects model was adopted. Our study revealed that there was no significant difference in terms of total blood loss (WMD = $-25.013$, 95% CI: $-51.002$ to $0.977$, $P = .059$; Fig. 2).

3.4.2. Hemoglobin decline

Six studies[10–13] showed the postoperative hemoglobin decline after TJA. There was no significant heterogeneity ($\chi^2 = 0.25$, df = 5, $I^2 = 0.0\%$, $P = .998$). Hemoglobin decline did not show significant differences between groups (WMD = $-0.090$, 95% CI: $-0.205$ to $0.024$, $P = .122$; Fig. 3).
3.4.3. Transfusion rates. Transfusion requirements were shown in six articles.\(^{[10-15]}\) We found no significant heterogeneity \((\chi^2 = 3.78, df = 5, I^2 = 0.0\%, P = .581)\); a fixed-effects model was adopted. There was no significant difference between groups regarding transfusion rates \(\text{RD} = -0.039, 95\% \text{ CI: } -0.080 \text{ to } 0.002, P = .062; \text{ Fig. 4).}\)

3.4.4. Duration of hospitalization. All RCTs provided the duration of hospitalization.\(^{[10-15]}\) There was no significant

### Table 1

| Refs.     | Study design | Cases (T/C) | Mean age (T/C) | Female patients (T/C) | Surgical procedure | TXA intervention | Transfusion trigger | Follow-up |
|-----------|--------------|-------------|----------------|-----------------------|--------------------|------------------|---------------------|-----------|
| Zohar et al\(^{[10]}\) | RCT          | 20/20       | 69/69          | 12/16                 | TKA                | max 15 mL/kg TKA; C: 1 g oral TKA | Hematocrit < 28% | 3 mo      |
| Irwin et al\(^{[14]}\) | CCT          | 302/2838    | 67.6/68.2      | 168/1442              | TKA & THA          | max 15 mg/kg TKA; C: 25 mg/kg | HB less than 7 g/dL | 2 mo      |
| Fillingham et al\(^{[12]}\) | RCT          | 34/37       | 62/63          | 21/26                 | TKA                | max 1 g TKA; C: 1.95 g oral TKA | HB less than 7 g/dL | NS        |
| Kayupov et al\(^{[11]}\) | RCT          | 40/43       | 60/55          | 40/33                 | THA                | max 1 g TKA; C: 1.95 g oral TKA | HB less than 7 g/dL | 2 mo      |
| Gortemoller et al\(^{[17]}\) | CCT          | 165/165     | 67/68          | 110/101               | TKA & THA          | max 15 mL/kg TKA; C: 1 g oral TKA | HB less than 7 g/dL | 6 mo      |
| Luo et al\(^{[13]}\) | RCT          | 60/60       | 67/68          | 33/32                 | THA                | max 20 mg/kg TKA; C: 2 g oral TKA | HB less than 7 g/dL | 3 mo      |

C = control group, CCT = case–control study, NS = net state, RCT = randomized controlled trial, T = TKA group, THA = total hip arthroplasty, TKA = total knee arthroplasty.
### Table 2
Methodological quality of the randomized controlled trials.

| Study          | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|----------------|---------------------------------------------|----------------------------------------|----------------------------------------------------------|-----------------------------------------------|----------------------------------------|-------------------------------------|------------|
| Fillingham 2015| +                                           | +                                      | ?                                                        | +                                             | +                                      | ?                                   | ?          |
| Kayupov 2017   | +                                           | +                                      | +                                                        | +                                             | +                                      | ?                                   | ?          |
| Luo, 2017      | +                                           | +                                      | ?                                                        | +                                             | +                                      | ?                                   | ?          |
| Zohar 2004     | +                                           | ?                                      | ?                                                        | ?                                             | +                                      | ?                                   | ?          |

### Table 3
Risk of bias.

- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias)
- Blinding of outcome assessment (detection bias)
- Incomplete outcome data (attrition bias)
- Selective reporting (reporting bias)
- Other bias

- Low risk of bias
- Unclear risk of bias
- High risk of bias
heterogeneity among articles ($\chi^2 = 2.80$, df = 5, $I^2 = 0.0\%$, $P = .731$). No significant difference in the duration of hospitalization was observed (WMD = 0.093, 95% CI: -0.280 to 0.094, $P = .331$; Fig. 5).

3.4.5. Deep vein thrombosis. Six studies\(^{[10-15]}\) showed the thrombotic complications of DVT. No significant statistical heterogeneity was found, and a fixed-effects model was used ($\chi^2 = 0.14$, df = 5, $I^2 = 0.0\%$, $P = 1.000$). Similar incidence of the risk of DVT was identified between groups (RD = -0.002, 95% CI: -0.010 to 0.006, $P = .597$; Fig. 6).

3.4.6. Pulmonary embolism. Six articles reported the thrombotic complications of PE following TJA\(^{[10-15]}\). A fixed-effects model was adopted ($\chi^2 = 0.14$, df = 5, $I^2 = 0.0\%$, $P = 1.000$). No significant difference was found in the PE incidence between the 2 groups (RD = -0.002, 95% CI: -0.012 to 0.008, $P = .722$; Fig. 7).

3.4.7. Subgroup analysis. Subgroup analysis was conducted for the outcome of blood loss, hemoglobin reduction, transfusion rates and duration of hospitalization (Table 5). The overall results demonstrated there was no significant difference between groups.

4. Discussion

To the best of our knowledge, this is the first systemic review to assess the efficacy between intravenous and oral forms of TXA application in TKA and THA. We found that oral TXA shows comparable efficacy to that of the intravenous forms after TKA and THA.

TXA, which acts as antifibrinolytic agent is famous for proven success in reducing peri- and postoperative blood loss and widely used in surgical procedure.\(^{[16-18]}\) TXA could be applied by various routes including intravenous, intraarticular, oral and intramuscular.

TXA is administered for approximately 2 hours via the oral, 30 minutes via the intramuscular, and 5 to 15 minutes via the intravenous routes\(^{[19]}\) in order to maintain the effective plasma concentration. König at al\(^{[20]}\) reported that topical administration of TXA for patients undergoing primary THA was effective

---

Table 4: Methodological quality of the nonrandomized controlled trials.

| Quality assessment for nonrandomized trials | Irwin et al\(^{[14]}\) | Gortemoller et al\(^{[17]}\) |
|--------------------------------------------|----------------|----------------|
| A clearly stated aim                        | 2              | 2              |
| Inclusion of consecutive patients           | 2              | 2              |
| Prospective data collection                 | 2              | 2              |
| Endpoints appropriate to the aim of the study | 2          | 2              |
| Unbiased assessment of the study endpoint   | 0              | 0              |
| A follow-up period appropriate to the aims of study | 2          | 2              |
| Less than 5% loss to follow-up              | 2              | 2              |
| Prospective calculation of the sample size  | 0              | 2              |
| An adequate control group                   | 2              | 2              |
| Contemporary groups                         | 2              | 2              |
| Baseline equivalence of groups              | 2              | 2              |
| Adequate statistical analyses               | 2              | 2              |
| Total score                                 | 20             | 22             |

**Overall (I-squared = 0.0%, $P = 0.960$)**

| Study          | WMD (95% CI)   | Weight |
|----------------|----------------|--------|
| Zohar (2004)   | -55.00 (-233.51, 123.51) | 2.12   |
| Irwin (2013)   | -29.00 (-58.66, 0.66)   | 76.80  |
| Fillingham (2015) | -19.00 (-163.47, 125.47) | 3.24   |
| Kayupov (2017) | 19.00 (-152.95, 190.95)  | 2.28   |
| Mary (2017)    | -20.00 (-85.10, 55.10)   | 11.98  |
| Luo (2017)     | 28.00 (-109.37, 165.37)  | 3.58   |
| Overall (I-squared = 0.0%, $P = 0.960$) | -25.01 (-51.00, 0.98) | 100.00 |

Figure 2. Forest plot showing the meta-analysis of total blood loss between the 2 groups.
| Study ID | WMD (95% CI)   | Weight |
|----------|----------------|--------|
| Zohar (2004) | -0.10 (-0.85, 0.65) | 2.35   |
| Irwin (2013)  | -0.10 (-0.24, 0.04)  | 65.12  |
| Fillingham (2015) | -0.14 (-1.12, 0.84) | 1.37   |
| Kayupov (2017) | -0.03 (-0.55, 0.49)  | 4.90   |
| Mary (2017)   | -0.10 (-0.36, 0.18)  | 19.37  |
| Luo (2017)    | 0.00 (-0.44, 0.44)   | 6.90   |
| Overall (I-squared = 0.0%, p = 0.998) | -0.09 (-0.20, 0.02) | 100.00 |

**Figure 3.** Forest plot showing the meta-analysis of hemoglobin decline between the 2 groups.

| Study ID | RD (95% CI)   | Weight |
|----------|----------------|--------|
| Zohar (2004) | -0.20 (-0.44, 0.04) | 2.30   |
| Irwin (2013)  | -0.02 (-0.07, 0.04)  | 62.86  |
| Fillingham (2015) | -0.06 (-0.29, 0.16) | 4.14   |
| Kayupov (2017) | -0.05 (-0.14, 0.04)  | 4.77   |
| Mary (2017)   | -0.09 (-0.19, 0.01)  | 19.01  |
| Luo (2017)    | -0.02 (-0.11, 0.08)   | 6.91   |
| Overall (I-squared = 0.0%, p = 0.581) | -0.04 (-0.08, 0.00) | 100.00 |

**Figure 4.** Forest plot showing the meta-analysis of transfusion rate between the 2 groups.
Figure 5. Forest plot showing the meta-analysis of length of hospital stay between the 2 groups.

Figure 6. Forest plot showing the meta-analysis of the incidence of DVT between the 2 groups.
in reducing blood loss. Fu et al\(^{[21]}\) performed a meta-analysis from 22 RCTs and showed that TXA is beneficial for patients undergoing TKA, which could significantly minimize total blood loss. However, oral routine of TXA in the setting of TJA have been limited due to the seldom published studies. Lee et al\(^{[22]}\) reported that oral TXA showed improved outcomes in blood sparing for hemoglobin decline and total blood loss in THA. Currently, whether oral administration of TXA was superior to intravenous routes in these patients was unknown. Our study revealed that oral TXA showed comparable efficacy to that of the intravenous forms after TKA and THA.

It was reported that TKA without antifibrinolytics was associated with massive blood loss ranging from 761 to 1784 mL\(^{[23–26]}\) and allogenic blood transfusion was frequently performed to relieve anemia. Potential side effects might occur, for instance, transmission of infection, possible hemolytic transfusion reactions, etc. Substantial high-quality RCTs and meta-analysis have been published to confirm that both intravenous and topical administration of TXA could diminish the need for allogeneic blood transfusions in patients undergoing TJA. Seol et al\(^{[27]}\) observed a 24% decrease in the requirement for transfusion in the intravenous TXA group compared control group after TKA. Whether oral administration of TXA was superior to intravenous TXA for reducing transfusion rate in TJA remained controversial. Meta-analysis is performed as major statistical method in the present study. It could strengthen statistical power and enlarge sample size by pooling results of published articles that could point out stronger evidence. Current meta-analysis revealed that the difference of transfusion requirements between oral and intravenous groups was not significant.

DVT is considered as a common postoperative complication, which may develop into PE and even result in death following

![Forest plot showing the meta-analysis of the incidence of PE between the 2 groups.](image)

**Figure 7.** Forest plot showing the meta-analysis of the incidence of PE between the 2 groups.

| Study         | ID            | RD (95% CI)   | Weight |
|---------------|---------------|---------------|--------|
| Zohar (2004)  |               | 0.00 (-0.09, 0.09) | 2.32  |
| Irwin (2013)  |               | -0.00 (-0.01, 0.01) | 62.74 |
| Fillingham (2015) |           | 0.00 (-0.05, 0.05) | 4.10  |
| Kayupov (2017) |               | 0.00 (-0.05, 0.05) | 4.80  |
| Mary (2017)   |               | -0.01 (-0.03, 0.02) | 19.10 |
| Luo (2017)    |               | 0.00 (-0.03, 0.03) | 6.96  |
| Overall \(i\)-squared = 0.0%, \(p = 1.000\)\) | -0.00 (-0.01, 0.01) | 100.00 |

**Table 5**

Subgroup analysis.

| Variables                  | Studies (n) | Patients (n) | \(P\) | WMD or RD (95% CI) | Heterogeneity \(P\)-value (\(I^2\)) | Model |
|----------------------------|-------------|--------------|-------|-------------------|-------------------------------------|-------|
| Total blood loss           |             |              |       |                   |                                     |       |
| RCTs                       | 4           | 314          | .94   | -3.07 [-80.66, 74.52] | .89 (0%)                          | Fixed |
| Postoperative hemoglobin level |             |              |       |                   |                                     |       |
| RCTs                       | 4           | 314          | .80   | -0.04 [-0.33, 0.25] | .99 (0%)                          | Fixed |
| Transfusion requirements   |             |              |       |                   |                                     |       |
| RCTs                       | 4           | 314          | .11   | -0.00 [-0.13, 0.01] | .54 (0%)                          | Fixed |
| Length of hospital stay    |             |              |       |                   |                                     |       |
| RCTs                       | 4           | 314          | .83   | -0.05 [-0.45, 0.36] | .98 (0%)                          | Fixed |

\(\text{CI}=\text{confidence interval, RCTs}=\text{randomized controlled trials, RD}=\text{risk difference, WMD}=\text{weighted mean difference.}\)
total joint arthroplasty.[28] Published articles have suggest a potential higher risk of thrombotic complication when TXA was used. This result might be due to the tendency of TXA, which is an antifibrinolytic agent, to promote the risk of clotting. Though the intravenous administration of TXA might be more likely to result in the formation of a thrombus because of the higher TXA level of blood concentration. There was no significant difference between both groups in terms of the risk of DVT or PE in the present analysis. However, further study was still necessary.

The limitations of this study were as follows: The small sample size might have affected the results of the meta-analysis; Functional outcome was not reported and could not be included in the meta-analysis; A large confidence interval for the results would influence the data interpretation and large sample size studies were required; All studies lacked long-term follow-up; Only English publications were included in our meta-analysis and publication bias was unavoidable.

5. Conclusion
Oral TXA shows comparable efficacy to that of the intravenous forms after total knee and hip arthroplasty. Due to the limited quality of evidence currently available, higher quality RCTs is necessary.

Author contributions
Dongxu Zhao conceived the design of the study, Kun-Chi Zhao and Ming-Ming Zhao performed and collected the data and contributed to the design of the study. Fei Wang finished the manuscript. All authors read and approved the final manuscript.

Conceptualization: Dong-Xu Zhao.
Data curation: Kun-Chi Zhao, Dong-Xu Zhao.
Formal analysis: Ming-Ming Zhao.
Writing – original draft: Fei Wang.
Writing – review & editing: Fei Wang.

References
[1] Saha R, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty?: Correct blood loss management should take hidden loss into account. Knee 2006;13:151–5.
[2] Browne JA, Adib F, Brown TE, et al. Transfusion rates are increasing following total hip arthroplasty: risk factors and outcomes. J Arthroplasty 2013;28(8 suppl):34–7.
[3] Harris RN, Moskal JT, Capps SG. Does tranexamic acid reduce blood transfusion cost for primary total hip arthroplasty? A case-control study. J Arthroplasty 2015;30:192–5.
[4] Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999;81:2–10.
[5] Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res 1997;85:195–206.
[6] Akoglu T, Buyuk M, Salduz A, et al. Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: a prospective clinical study. Acta Orthop Traumatol Turc 2016;50:429–31.
[7] Poeran J, Rasul R, Suzuki S, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014;349:g4829.
[8] Lee QJ, Ching WY, Wong YC. Blood sparing efficacy of oral tranexamic acid in primary total knee arthroplasty: a randomized controlled trial. Knee Surg Relat Res 2017;29:57–62.
[9] Dent O. Methodological index for non-randomized studies. ANZ J Surg 2003;73:675–6.
[10] Zohar E, Ellis M, Ifrach N, et al. The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement. Anesth Analg 2004;99:1679–83.
[11] Kayupov E, Fillingham YA, Okroy K, et al. Oral and intravenous tranexamic acid are equivalent at reducing blood loss following total hip arthroplasty: a randomized controlled trial. J Bone Joint Am 2017;99:373–8.
[12] Fillingham YA, Kayupov E, Plummer DR, et al. Rand Young Investigator’s Award: a randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: the same efficacy at lower cost? J Arthroplasty 2016;31(9 suppl):26–30.
[13] Liao ZY, Wang HY, Wang D, et al. Oral vs intravenous vs topical tranexamic acid in primary hip arthroplasty: a prospective, randomized, double-blind, controlled study. J Arthroplasty 2018;33:786–93.
[14] Irwin A, Khan SK, Jameson SS, et al. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J 2013;95-B:556–61.
[15] Gortemoller MA, Allen B, Forsyth R, et al. Comparison of oral and intravenous tranexamic acid for prevention of perioperative blood loss in total knee and total hip arthroplasty. Ann Pharmacother 2017;52:246–50.
[16] Shaalan MM, Ahmed MR, Farhan RE, et al. Efficacy of tranexamic acid on myomectomy-associated blood loss in patients with multiple myomas: a randomized controlled clinical trial. Reproduct Sci 2016;23:908–12.
[17] Prokopchuk-Gauk O, Rosin MW, Mysyk TR, et al. Oral-route tranexamic acid to reduce blood loss in coronary artery bypass graft surgery: a randomized controlled trial. Can J Anaesth 2016;63:1110–1.
[18] Massicotte L, Denault AY, Beaulieu D, et al. Aprotinin versus tranexamic acid during liver transplantation: impact on blood product requirements and survival. Transplantation 2011;91:1273–8.
[19] Ronday HK, Te Koppele JM, Greenwald RA, et al. Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary collagen cross-link excretion in both experimental and rheumatoid arthritis. Br J Rheumatol 1998;37:34–8.
[20] Kong G, Hamlin BR, Waters JH. Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty. J Arthroplasty 2013;28:1473–6.
[21] Fu DJ, Chen C, Guo L, et al. Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Traumatol 2013;16:67–76.
[22] Lee QJ, Ching WY, Wong YC. Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. J Arthroplasty 2017;32:139–42.
[23] Veen M, Sorensen JV, Madsen F, et al. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand 2002;46:1206–10.
[24] Hiippala S, Strid L, Wennerstrand M, et al. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. J Arthroplasty 1993;8:344–47.
[25] Camarasa MA, Olle G, Serra-Prat M, et al. Efficacy of aminopropran, tranexamic acids in the control of bleeding during total hip knee replacement: a randomized clinical trial. Acta Anaesthesiol Scand 2002;46:1206–10.
[26] Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br 1996;78:434–40.
[27] Soel VJ, Seon JK, Lee SH, et al. Effect of tranexamic acid on blood loss and blood transfusion after total knee arthroplasty. Knee Surg Relat Res 2016;28:188–93.
[28] Wang C, Han Z, Zhang T, et al. The efficacy of a thrombin-based hemostatic agent in primary total knee arthroplasty: a meta-analysis. J Orthop Surg Res 2014;9:90.